Last reviewed · How we verify
in vitro sensitivity-directed chemotherapy — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
in vitro sensitivity-directed chemotherapy (in vitro sensitivity-directed chemotherapy) — Children's Oncology Group. In vitro sensitivity-directed chemotherapy selects chemotherapeutic agents based on the sensitivity of tumor cells tested in a laboratory setting.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| in vitro sensitivity-directed chemotherapy TARGET | in vitro sensitivity-directed chemotherapy | Children's Oncology Group | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- in vitro sensitivity-directed chemotherapy CI watch — RSS
- in vitro sensitivity-directed chemotherapy CI watch — Atom
- in vitro sensitivity-directed chemotherapy CI watch — JSON
- in vitro sensitivity-directed chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). in vitro sensitivity-directed chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/in-vitro-sensitivity-directed-chemotherapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab